- Home
- SOGP vs APLM Comparison
SOGP vs APLM Comparison
Compare SOGP & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOGP
- APLM
- Stock Information
- Founded
- SOGP 2010
- APLM 2016
- Country
- SOGP Singapore
- APLM United States
- Employees
- SOGP N/A
- APLM N/A
- Industry
- SOGP
- APLM Blank Checks
- Sector
- SOGP
- APLM Finance
- Exchange
- SOGP NYSE
- APLM Nasdaq
- Market Cap
- SOGP 6.9M
- APLM 6.9M
- IPO Year
- SOGP 2020
- APLM N/A
- Fundamental
- Price
- SOGP $5.98
- APLM $6.49
- Analyst Decision
- SOGP
- APLM
- Analyst Count
- SOGP 0
- APLM 0
- Target Price
- SOGP N/A
- APLM N/A
- AVG Volume (30 Days)
- SOGP 1.9M
- APLM 7.8K
- Earning Date
- SOGP 07-15-2025
- APLM 08-13-2025
- Dividend Yield
- SOGP N/A
- APLM N/A
- EPS Growth
- SOGP N/A
- APLM N/A
- EPS
- SOGP N/A
- APLM N/A
- Revenue
- SOGP $278,363,908.00
- APLM $198,000.00
- Revenue This Year
- SOGP $48.88
- APLM $415.15
- Revenue Next Year
- SOGP N/A
- APLM N/A
- P/E Ratio
- SOGP N/A
- APLM N/A
- Revenue Growth
- SOGP N/A
- APLM N/A
- 52 Week Low
- SOGP $1.18
- APLM $4.47
- 52 Week High
- SOGP $6.20
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- SOGP 77.70
- APLM 47.85
- Support Level
- SOGP $3.71
- APLM $6.21
- Resistance Level
- SOGP $6.00
- APLM $6.80
- Average True Range (ATR)
- SOGP 0.77
- APLM 0.52
- MACD
- SOGP 0.31
- APLM 0.00
- Stochastic Oscillator
- SOGP 95.28
- APLM 51.61
About SOGP SOUND GROUP INC SPON ADS EA REP 200 ORD SHS(POST SPLIT)
Sound Group Inc is a world-wide audio-centric social and entertainment company. It Leverages broad product portfolio and in-house technologies, Sound Group caters to user interest in audio entertainment and social networking. Sound Group nurtures a globally diverse and inclusive team, drawing on talent from various countries and regions world-wide.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.